1. Executive Summary 1. Market Overview 1. Market Landscape 1. Market ecosystem 2. Value chain analysis 1. Market Sizing 1. Market definition 2. Market segment analysis 3. Market size 2019 4. Market outlook: Forecast for 2019 - 2024 1. Five Forces Analysis 1. Five Forces Summary 2. Bargaining power of buyers 3. Bargaining power of suppliers 4. Threat of new entrants 5. Threat of substitutes 6. Threat of rivalry 7. Market condition 1. Market Segmentation by Product 1. Market segments 2. Comparison by Product placement 3. Antidepressants - Market size and forecast 2019-2024 4. Anxiolytics - Market size and forecast 2019-2024 5. Other PTSD therapeutics - Market size and forecast 2019-2024 6. Market opportunity by Product 1. Customer landscape 1. Overview 1. Geographic Landscape 1. Geographic segmentation 2. Geographic comparison 3. North America - Market size and forecast 2019-2024 4. APAC - Market size and forecast 2019-2024 5. Europe - Market size and forecast 2019-2024 6. South America - Market size and forecast 2019-2024 7. MEA - Market size and forecast 2019-2024 8. Key leading countries 9. Market opportunity by geography 1. Drivers, Challenges, and Trends 1. Market drivers 2. Volume driver - Demand led growth 3. Volume driver - Supply led growth 4. Volume driver - External factors 5. Volume driver - Demand shift in adjacent markets 6. Price driver - Inflation 7. Price driver - Shift from lower to higher priced units 8. Market challenges 9. Market trends 1. Vendor Landscape 1. Overview 2. Vendor landscape 3. Landscape disruption 1. Vendor Analysis 1. Vendors covered 2. Market positioning of vendors 3. AstraZeneca Plc 4. Azevan Pharmaceuticals Inc. 5. Bionomics Ltd. 6. Eli Lilly and Co. 7. GlaxoSmithKline Plc 8. H. Lundbeck AS 9. Mylan NV 10. Neurocrine Biosciences Inc. 11. Novartis International AG 12. Pfizer Inc. 1. Appendix 1. Scope of the report 2. Currency conversion rates for US$ 3. Research methodology 4. List of abbreviations Exhibits 1.Key Finding 1 2.Key Finding 2 3.Key Finding 3 4.Key Finding 4 5.Key Finding 5 6.Key Finding 6 7.Key Finding 7 8.Market in focus 9.Parent market 10.Market characteristics 11.Product / Service portfolio of key vendors included in the market definition 12.Market segments 13.Global - Market size and forecast 2019 - 2024 ($ million) 14.Global market: Year-over-year growth 2019 - 2024 (%) 15.Five forces analysis 2019 & 2024 16.Bargaining power of buyers 17.Bargaining power of suppliers 18.Threat of new entrants 19.Threat of substitutes 20.Threat of rivalry 21.Market condition - Five forces 2019 22.Product placement - Market share 2019-2024 (%) 23.Comparison by Product placement 24.Antidepressants - Market size and forecast 2019-2024 ($ million) 25.Antidepressants - Year-over-year growth 2019-2024 (%) 26.Anxiolytics - Market size and forecast 2019-2024 ($ million) 27.Anxiolytics - Year-over-year growth 2019-2024 (%) 28.Other PTSD therapeutics - Market size and forecast 2019-2024 ($ million) 29.Other PTSD therapeutics - Year-over-year growth 2019-2024 (%) 30. Market opportunity by Product 31.Customer landscape 32.Market share by geography 2019-2024 (%) 33.Geographic comparison 34.North America - Market size and forecast 2019-2024 ($ million) 35.North America - Year-over-year growth 2019-2024 (%) 36.APAC - Market size and forecast 2019-2024 ($ million) 37.APAC - Year-over-year growth 2019-2024 (%) 38.Europe - Market size and forecast 2019-2024 ($ million) 39.Europe - Year-over-year growth 2019-2024 (%) 40.South America - Market size and forecast 2019-2024 ($ million) 41.South America - Year-over-year growth 2019-2024 (%) 42.MEA - Market size and forecast 2019-2024 ($ million) 43.MEA - Year-over-year growth 2019-2024 (%) 44.Key leading countries 45.Market opportunity by geography ($ million) 46.Impact of drivers 47.Impact of challenges 48.Landscape disruption 49.Industry risks 50.Vendors covered 51.Market positioning of vendors 52.AstraZeneca Plc - Overview (1/3) 53.AstraZeneca Plc - Overview (2/3) 54.AstraZeneca Plc - Overview (3/3) 55.AstraZeneca Plc - Product and service 56.AstraZeneca Plc - Key offerings 57.AstraZeneca Plc - Key customers 58.AstraZeneca Plc - Segment focus 59.Azevan Pharmaceuticals Inc. - Overview (1/3) 60.Azevan Pharmaceuticals Inc. - Overview (2/3) 61.Azevan Pharmaceuticals Inc. - Overview (3/3) 62.Azevan Pharmaceuticals Inc. - Product and service 63.Azevan Pharmaceuticals Inc. - Key offerings 64.Azevan Pharmaceuticals Inc. - Key customers 65.Azevan Pharmaceuticals Inc. - Segment focus 66.Bionomics Ltd. - Overview (1/3) 67.Bionomics Ltd. - Overview (2/3) 68.Bionomics Ltd. - Overview (3/3) 69.Bionomics Ltd. - Business segments 70.Bionomics Ltd. - Key offerings 71.Bionomics Ltd. - Key customers 72.Bionomics Ltd. - Segment focus 73.Eli Lilly and Co. - Overview (1/3) 74.Eli Lilly and Co. - Overview (2/3) 75.Eli Lilly and Co. - Overview (3/3) 76.Eli Lilly and Co. - Business segments 77.Eli Lilly and Co. - Key offerings 78.Eli Lilly and Co. - Key customers 79.Eli Lilly and Co. - Segment focus 80.GlaxoSmithKline Plc - Overview (1/3) 81.GlaxoSmithKline Plc - Overview (2/3) 82.GlaxoSmithKline Plc - Overview (3/3) 83.GlaxoSmithKline Plc - Business segments 84.GlaxoSmithKline Plc - Key offerings 85.GlaxoSmithKline Plc - Key customers 86.GlaxoSmithKline Plc - Segment focus 87.H. Lundbeck AS - Overview (1/3) 88.H. Lundbeck AS - Overview (2/3) 89.H. Lundbeck AS - Overview (3/3) 90.H. Lundbeck AS - Product and service 91.H. Lundbeck AS - Key offerings 92.H. Lundbeck AS - Key customers 93.H. Lundbeck AS - Segment focus 94.Mylan NV - Overview (1/3) 95.Mylan NV - Overview (2/3) 96.Mylan NV - Overview (3/3) 97.Mylan NV - Business segments 98.Mylan NV - Key offerings 99.Mylan NV - Key customers 100.Mylan NV - Segment focus 101.Neurocrine Biosciences Inc. - Overview (1/3) 102.Neurocrine Biosciences Inc. - Overview (2/3) 103.Neurocrine Biosciences Inc. - Overview (3/3) 104.Neurocrine Biosciences Inc. - Business segments 105.Neurocrine Biosciences Inc. - Key offerings 106.Neurocrine Biosciences Inc. - Key customers 107.Neurocrine Biosciences Inc. - Segment focus 108.Novartis International AG - Overview (1/3) 109.Novartis International AG - Overview (2/3) 110.Novartis International AG - Overview (3/3) 111.Novartis International AG - Business segments 112.Novartis International AG - Key offerings 113.Novartis International AG - Key customers 114.Novartis International AG - Segment focus 115.Pfizer Inc. - Overview (1/3) 116.Pfizer Inc. - Overview (2/3) 117.Pfizer Inc. - Overview (3/3) 118.Pfizer Inc. - Business segments 119.Pfizer Inc. - Key offerings 120.Pfizer Inc. - Key customers 121.Pfizer Inc. - Segment focus 122.Currency conversion rates for US$ 123.Research Methodology 124.Validation techniques employed for market sizing 125.Information sources 126.List of abbreviations

AstraZeneca Plc Azevan Pharmaceuticals Inc. Bionomics Ltd. Eli Lilly and Co. GlaxoSmithKline Plc H. Lundbeck AS Mylan NV Neurocrine Biosciences Inc. Novartis International AG Pfizer Inc.